No Data
Cantor Fitzgerald Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $44
Express News | Cantor Fitzgerald Initiates Coverage On Apellis Pharmaceuticals With Overweight Rating, Announces Price Target of $44
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Analysts' Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Apellis Pharmaceuticals (APLS) and Eton Pharmaceuticals (ETON)
William Blair Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Market Expansion and Growth Prospects
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
been hot today but that's getting into buying range for me..... EBS middle size company that got a new CEO last year completely changed things around since for EBS. take a look at who owns EBS and how much together. this small float is trading around 50% since half or more is already bought up by insiders or tutes